Christiana Stamoulis

Currently holds positions in Incyte Corp and Hologic Inc

Position	Company	Period
Chief Financial Officer, Executive Vice President	Incyte Corp	Feb. 11, 2019 -
Independent Director	Hologic Inc	Nov. 1, 2011 -
President, Chief Financial Officer	Cogent Biosciences Inc	Feb. 1, 2018 - Jan. 31, 2019
Chief Financial Officer, Head - Corporate Development	Cogent Biosciences Inc	Jan. 12, 2015 - Feb. 1, 2018
Senior Vice President - Corporate Strategy and Business Development	Vertex Pharmaceuticals Inc	Oct. 1, 2009 - Jan. 1, 2013

• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings

Download results Settings

Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other

Notification date	Transaction date	Company	B/S Transaction type	Nb. shares Price Value	Number of shares	Price	Value
2025-12-15	2025-12-15	Incyte Corp (INCY)	PrS Proposed sale	96,611 391.09 US$4,102,015	96,611	391.09	US$4,102,015
2025-11-12	2025-11-12	Incyte Corp (INCY)	PrS Proposed sale	8,208 459.02 US$1,173,363	8,208	459.02	US$1,173,363
2025-11-03	2025-11-03	Incyte Corp (INCY)	PrS Proposed sale	23,330 102.70 US$969,719	23,330	102.70	US$969,719
2025-10-30	2025-10-30	Incyte Corp (INCY)	PrS Proposed sale	14,986 94.00 US$1,408,684	14,986	94.00	US$1,408,684
2025-10-22	2025-10-20	Hologic Inc (HOLX)	PlS Planned sale	7,402 -13.5% 73.07 US$540,864	7,402 -13.5%	73.07	US$540,864
2025-10-20	2025-10-20	Hologic Inc (HOLX)	PrS Proposed sale	7,402 73.07 US$540,864	7,402	73.07	US$540,864
2024-07-19	2024-07-17	Hologic Inc (HOLX)	PlS Planned sale	9,039 -16.6% 79.50 US$718,600	9,039 -16.6%	79.50	US$718,600
2024-07-17	2024-07-17	Hologic Inc (HOLX)	PrS Proposed sale	9,039 79.50 US$718,600	9,039	79.50	US$718,600
2020-11-06	2020-11-04	Hologic Inc (HOLX)	PlS Planned sale	11,146 -22.1% 74.00 US$824,804	11,146 -22.1%	74.00	US$824,804